Download PDF
Semin Thromb Hemost 2014; 40(03): 382-394
DOI: 10.1055/s-0034-1371005
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Management of Complications Related to Central Venous Catheters in Cancer Patients: An Update

Birgit Linnemann
1   Division of Vascular Medicine, Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
04 March 2014 (online)

    Permissions and Reprints

Abstract

Central venous catheters (CVCs) are important for the treatment of patients with cancer, especially in the perioperative and palliative care settings. These devices not only allow for the administration of chemotherapy, parenteral nutrition, and other intravenous therapies, but they may also improve the patients' quality of life by reducing the need for repeated peripheral venipunctures. Thrombotic and infectious complications are common, especially in the long-term use of CVCs. There are different types of thrombotic complications associated with CVCs, that is, a thrombotic occlusion of the catheter, a mural thrombus at the catheter tip and classical deep vein thrombosis, which occurs most frequently in the upper extremity where the majority of long-term catheters are inserted. Infections are common complications associated with CVCs. Patients with cancer who receive intensive chemotherapy and those patients who undergo hematopoietic stem cell transplantation have a markedly increased risk for insertion site and bloodstream infections. In this review, the epidemiology and risk factors that predispose patients to CVC-related thrombosis and infection are discussed. The diagnostic and therapeutic options according to the published data and the current guidelines are summarized and data for establishing primary and secondary preventative strategies are provided.

Keywords

central venous catheter - cancer - thrombosis - infection
 

  • References

  • 1 Schiffer CA, Mangu PB, Wade JC , et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31 (10) 1357-1370
    CrossrefPubMedGoogle Scholar
  • 2 Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13 (1) 233-238
    PubMedGoogle Scholar
  • 3 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19) 3665-3675
    CrossrefPubMedGoogle Scholar
  • 4 Mueller BU, Skelton J, Callender DP , et al. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10 (12) 1943-1948
    PubMedGoogle Scholar
  • 5 Bonizzoli M, Batacchi S, Cianchi G , et al. Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients. Intensive Care Med 2011; 37 (2) 284-289
    CrossrefPubMedGoogle Scholar
  • 6 Turcotte S, Dubé S, Beauchamp G. Peripherally inserted central venous catheters are not superior to central venous catheters in the acute care of surgical patients on the ward. World J Surg 2006; 30 (8) 1605-1619
    CrossrefPubMedGoogle Scholar
  • 7 Saber W, Moua T, Williams EC , et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9 (2) 312-319
    CrossrefPubMedGoogle Scholar
  • 8 Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev 2012; 3: CD004084
    PubMedGoogle Scholar
  • 9 Biffi R, Orsi F, Pozzi S , et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20 (5) 935-940
    CrossrefPubMedGoogle Scholar
  • 10 O'Grady NP, Alexander M, Burns LA , et al; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52 (9) e162-e193
    CrossrefPubMedGoogle Scholar
  • 11 van de Wetering MD, van Woensel JB. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database Syst Rev 2007; 1 (1) CD003295
    PubMedGoogle Scholar
  • 12 Luciani A, Clement O, Halimi P , et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220 (3) 655-660
    CrossrefPubMedGoogle Scholar
  • 13 Lavau-Denes S, Lacroix P, Maubon A , et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 2013; 72 (1) 65-73
    CrossrefPubMedGoogle Scholar
  • 14 Verso M, Agnelli G, Kamphuisen PW , et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3 (2) 117-122
    CrossrefPubMedGoogle Scholar
  • 15 Lee AY, Levine MN, Butler G , et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24 (9) 1404-1408
    CrossrefPubMedGoogle Scholar
  • 16 Peris A, Zagli G, Bonizzoli M , et al. Implantation of 3951 long-term central venous catheters: performances, risk analysis, and patient comfort after ultrasound-guidance introduction. Anesth Analg 2010; 111 (5) 1194-1201
    CrossrefPubMedGoogle Scholar
  • 17 Cotogni P, Pittiruti M, Barbero C, Monge T, Palmo A, Boggio Bertinet D. Catheter-related complications in cancer patients on home parenteral nutrition: a prospective study of over 51,000 catheter days. JPEN J Parenter Enteral Nutr 2013; 37 (3) 375-383
    CrossrefPubMedGoogle Scholar
  • 18 Di Nisio M, Ferrante N, De Tursi M , et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (5) 1049-1054
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 20 Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119 (3) 648-655
    CrossrefPubMedGoogle Scholar
  • 21 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
    CrossrefPubMedGoogle Scholar
  • 22 Barry E, DeAngelo DJ, Neuberg D , et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25 (7) 813-819
    CrossrefPubMedGoogle Scholar
  • 23 Palumbo A, Rajkumar SV, Dimopoulos MA , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (2) 414-423
    CrossrefPubMedGoogle Scholar
  • 24 van Marion AM, Auwerda JJ, Lisman T , et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32 (7) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 25 Cives M, Milano A, Dammacco F, Silvestris F. Lenalidomide in multiple myeloma: current experimental and clinical data. Eur J Haematol 2012; 88 (4) 279-291
    CrossrefPubMedGoogle Scholar
  • 26 Barni S, Labianca R, Agnelli G , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179
    CrossrefPubMedGoogle Scholar
  • 27 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
    CrossrefPubMedGoogle Scholar
  • 28 Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res 2012; 130 (1) 27-31
    CrossrefPubMedGoogle Scholar
  • 29 Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115 (19) 4442-4449
    CrossrefPubMedGoogle Scholar
  • 30 Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9 (8) 437-449
    CrossrefPubMedGoogle Scholar
  • 31 Marnejon T, Angelo D, Abu Abdou A, Gemmel D. Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. J Vasc Access 2012; 13 (2) 231-238
    CrossrefPubMedGoogle Scholar
  • 32 Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag 2013; 9: 207-228
    PubMedGoogle Scholar
  • 33 Baskin JL, Pui CH, Reiss U , et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374 (9684) 159-169
    CrossrefPubMedGoogle Scholar
  • 34 Toure A, Chambrier C, Vanhems P, Lombard-Bohas C, Souquet JC, Ecochard R. Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients. Clin Nutr 2013; 32 (6) 1050-1054
    CrossrefPubMedGoogle Scholar
  • 35 Touré A, Vanhems P, Lombard-Bohas C , et al. Totally implantable central venous access port infections in patients with digestive cancer: incidence and risk factors. Am J Infect Control 2012; 40 (10) 935-939
    CrossrefPubMedGoogle Scholar
  • 36 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27 (29) 4858-4864
    CrossrefPubMedGoogle Scholar
  • 37 Borchardt RA, Raad I. Bloodstream infections: the risks and benefits of intravascular catheters. JAAPA 2012; 25 (8) 21-22
    PubMedGoogle Scholar
  • 38 van Rooden CJ, Schippers EF, Barge RM , et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23 (12) 2655-2660
    PubMedGoogle Scholar
  • 39 Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25 (2) 147-155
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30 (4) 908-912
    CrossrefPubMedGoogle Scholar
  • 41 Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. J Adv Nurs 2009; 65 (10) 2007-2021
    CrossrefPubMedGoogle Scholar
  • 42 Muslimani AA, Ricaurte B, Daw HA. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol 2007; 82 (7) 652-655
    CrossrefPubMedGoogle Scholar
  • 43 Boraks P, Seale J, Price J , et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101 (3) 483-486
    CrossrefPubMedGoogle Scholar
  • 44 Monreal M, Alastrue A, Rull M , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75 (2) 251-253
    PubMedGoogle Scholar
  • 45 Couban S, Goodyear M, Burnell M , et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23 (18) 4063-4069
    CrossrefPubMedGoogle Scholar
  • 46 Karthaus M, Kretzschmar A, Kröning H , et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17 (2) 289-296
    PubMedGoogle Scholar
  • 47 Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Büller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5 (9) 1878-1882
    CrossrefPubMedGoogle Scholar
  • 48 Verso M, Agnelli G, Bertoglio S , et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23 (18) 4057-4062
    CrossrefPubMedGoogle Scholar
  • 49 Young AM, Billingham LJ, Begum G , et al; WARP Collaborative Group, UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373 (9663) 567-574
    CrossrefPubMedGoogle Scholar
  • 50 Akl EA, Vasireddi SR, Gunukula S , et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011; 4 (4) CD006468
    PubMedGoogle Scholar
  • 51 Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5 (12) 2552-2554
    CrossrefPubMedGoogle Scholar
  • 52 Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99 (1) 38-43
    PubMedGoogle Scholar
  • 53 Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters—a reappraisal of the evidence. Br J Cancer 2006; 94 (2) 189-194
    CrossrefPubMedGoogle Scholar
  • 54 Kahn SR, Lim W, Dunn AS , et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e195S-e226S
    CrossrefPubMedGoogle Scholar
  • 55 Akl EA, Gunukula S, Barba M , et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011; 4 (4) CD006652
    PubMedGoogle Scholar
  • 56 McLaws ML, Burrell AR. Zero risk for central line-associated bloodstream infection: are we there yet?. Crit Care Med 2012; 40 (2) 388-393
    CrossrefPubMedGoogle Scholar
  • 57 Covey AM, Toro-Pape FW, Thornton RH , et al. Totally implantable venous access device placement by interventional radiologists: are prophylactic antibiotics necessary?. J Vasc Interv Radiol 2012; 23 (3) 358-362
    CrossrefPubMedGoogle Scholar
  • 58 Timsit JF, Schwebel C, Bouadma L , et al; Dressing Study Group. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009; 301 (12) 1231-1241
    CrossrefPubMedGoogle Scholar
  • 59 Weber JM, Sheridan RL, Fagan S, Ryan CM, Pasternack MS, Tompkins RG. Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population. J Burn Care Res 2012; 33 (4) 539-543
    CrossrefPubMedGoogle Scholar
  • 60 Raad I, Mohamed JA, Reitzel RA , et al. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. Antimicrob Agents Chemother 2012; 56 (2) 935-941
    CrossrefPubMedGoogle Scholar
  • 61 Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis 2008; 21 (3) 235-245
    CrossrefPubMedGoogle Scholar
  • 62 Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43 (4) 474-484
    CrossrefPubMedGoogle Scholar
  • 63 Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 2003; 18 (12) 2688-2690
    PubMedGoogle Scholar
  • 64 Slobbe L, Doorduijn JK, Lugtenburg PJ , et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS ONE 2010; 5 (5) e10840
    CrossrefPubMedGoogle Scholar
  • 65 Dümichen MJ, Seeger K, Lode HN , et al. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect 2012; 80 (4) 304-309
    CrossrefPubMedGoogle Scholar
  • 66 Rosenblatt J, Reitzel R, Dvorak T, Jiang YY, Hachem R, Raad II. Glyceryl trinitrate complements citrate and ethanol in a novel antimicrobial catheter lock solution. Antimicrob Agents Chemother 2013; 57: 3555-3560
    CrossrefPubMedGoogle Scholar
  • 67 Maki DG, Ash SR, Winger RK, Lavin P ; AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 2011; 39 (4) 613-620
    CrossrefPubMedGoogle Scholar
  • 68 Vescia S, Baumgärtner AK, Jacobs VR , et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19 (1) 9-15
    PubMedGoogle Scholar
  • 69 Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER ; COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12 (8) 951-955
    CrossrefPubMedGoogle Scholar
  • 70 Deitcher SR, Fesen MR, Kiproff PM , et al; Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20 (1) 317-324
    CrossrefPubMedGoogle Scholar
  • 71 Linnemann B, Lindhoff-Last E. Risk factors, management and primary prevention of thrombotic complications related to the use of central venous catheters. Vasa 2012; 41 (5) 319-332
    CrossrefPubMedGoogle Scholar
  • 72 Levitan N, Dowlati A, Remick SC , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (5) 285-291
    CrossrefPubMedGoogle Scholar
  • 73 Linnemann B, Meister F, Schwonberg J, Schindewolf M, Zgouras D, Lindhoff-Last E ; MAISTHRO registry. Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 2008; 100 (3) 440-446
    PubMedGoogle Scholar
  • 74 Muñoz FJ, Mismetti P, Poggio R , et al; RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133 (1) 143-148
    CrossrefPubMedGoogle Scholar
  • 75 Spencer FA, Emery C, Lessard D, Goldberg RJ ; Worcester Venous Thromboembolism Study. Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 2007; 120 (8) 678-684
    CrossrefPubMedGoogle Scholar
  • 76 Mandalà M, Curigliano G, Bucciarelli P , et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15 (4) 590-593
    CrossrefPubMedGoogle Scholar
  • 77 Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89 (2) 201-206
    PubMedGoogle Scholar
  • 78 Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6 (1) 70-75
    PubMedGoogle Scholar
  • 79 De Cicco M, Matovic M, Balestreri L , et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb Res 1995; 78 (2) 127-137
    CrossrefPubMedGoogle Scholar
  • 80 Kucher N. Clinical practice. Deep venous thrombosis of the upper extremities. N Engl J Med 2011; 364: 861-869
    CrossrefPubMedGoogle Scholar
  • 81 Mai C, Hunt D. Upper-extremity deep venous thrombosis: a review. Am J Med 2011; 124 (5) 402-407
    CrossrefPubMedGoogle Scholar
  • 82 Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356 (18) 1862-1869
    CrossrefPubMedGoogle Scholar
  • 83 Arnhjort T, Persson LM, Rosfors S, Ludwigs U, Lärfars G. Primary deep vein thrombosis in the upper limb: A retrospective study with emphasis on pathogenesis and late sequelae. Eur J Intern Med 2007; 18 (4) 304-308
    CrossrefPubMedGoogle Scholar
  • 84 Baarslag HJ, Koopman MM, Hutten BA , et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004; 15 (8) 503-507
    CrossrefPubMedGoogle Scholar
  • 85 Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117 (6) 609-614
    CrossrefPubMedGoogle Scholar
  • 86 Hingorani A, Ascher E, Marks N , et al. Morbidity and mortality associated with brachial vein thrombosis. Ann Vasc Surg 2006; 20 (3) 297-300
    CrossrefPubMedGoogle Scholar
  • 87 Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110 (5) 566-570
    CrossrefPubMedGoogle Scholar
  • 88 Monreal M, Raventos A, Lerma R , et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. Thromb Haemost 1994; 72 (4) 548-550
    PubMedGoogle Scholar
  • 89 Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremities. Circulation 2004; 110: 566-572
    CrossrefPubMedGoogle Scholar
  • 90 Bates SM, Jaeschke R, Stevens SM , et al; American College of Chest Physicians. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e351S-e418S
    CrossrefPubMedGoogle Scholar
  • 91 Debourdeau P, Farge D, Beckers M , et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11 (1) 71-80
    CrossrefPubMedGoogle Scholar
  • 92 Linnemann B, Lindhoff-Last E. [Management of catheter-related upper extremity deep vein thrombosis]. Zentralbl Chir 2013; 138 (Suppl. 02) e86-e94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Di Nisio M, Van Sluis GL, Bossuyt PM, Büller HR, Porreca E, Rutjes AW. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8 (4) 684-692
    CrossrefPubMedGoogle Scholar
  • 94 Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3 (11) 2409-2419
    CrossrefPubMedGoogle Scholar
  • 95 Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45 (1) 38-43
    CrossrefPubMedGoogle Scholar
  • 96 Kim H, Chung JW, Park JH , et al. Role of CT venography in the diagnosis and treatment of benign thoracic central venous obstruction. Korean J Radiol 2003; 4 (3) 146-152
    CrossrefPubMedGoogle Scholar
  • 97 Constans J, Salmi LR, Sevestre-Pietri MA , et al. A clinical prediction score for upper extremity deep venous thrombosis. Thromb Haemost 2008; 99 (1) 202-207
    PubMedGoogle Scholar
  • 98 Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17 (3) 225-226
    CrossrefPubMedGoogle Scholar
  • 99 Kovacs MJ, Kahn SR, Rodger M , et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5 (8) 1650-1653
    CrossrefPubMedGoogle Scholar
  • 100 Savage KJ, Wells PS, Schulz V , et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82 (3) 1008-1010
    PubMedGoogle Scholar
  • 101 Streiff MB ; National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133
    CrossrefPubMedGoogle Scholar
  • 102 Farge D, Debourdeau P, Beckers M , et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (1) 56-70
    CrossrefPubMedGoogle Scholar
  • 103 Lee AYY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 104 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A , et al; RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (Suppl. 02) S58-S61
    CrossrefPubMedGoogle Scholar
  • 105 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 106 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 107 Jones MA, Lee DY, Segall JA , et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51 (1) 108-113
    CrossrefPubMedGoogle Scholar
  • 108 Sullivan VV, Wolk SW, Lampman RM, Prager RL, Hankin FM, Whitehouse Jr WM. Upper extremity venous gangrene following coronary artery bypass. A case report and review of the literature. J Cardiovasc Surg (Torino) 2001; 42 (4) 551-554
    PubMedGoogle Scholar
  • 109 Chopra V, Anand S, Krein SL, Chenoweth C, Saint S. Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence. Am J Med 2012; 125 (8) 733-741
    CrossrefPubMedGoogle Scholar
  • 110 Chopra V, Anand S, Hickner A , et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013; 382 (9889) 311-325
    CrossrefPubMedGoogle Scholar
  • 111 Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 2008; 19 (3) 433-442
    PubMedGoogle Scholar
  • 112 Rodríguez L, Ethier MC, Phillips B, Lehrnbecher T, Doyle J, Sung L. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review. Support Care Cancer 2012; 20 (12) 3261-3267
    CrossrefPubMedGoogle Scholar
  • 113 Mermel LA, Allon M, Bouza E , et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 (1) 1-45
    CrossrefPubMedGoogle Scholar
  • 114 Béraud G, Seguy D, Alfandari S , et al. Factors associated with recurrence of catheter-related bloodstream infections in home parenteral nutrition patients. Eur J Clin Microbiol Infect Dis 2012; 31 (11) 2929-2933
    CrossrefPubMedGoogle Scholar